- UME commited to offering high-quality COVID-19 services, solutions and supplies.
- To effectively end worldwide pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical.
- CareStart antigen test features 10-minute processing time, identifies acute infection, helps provide critical answers.
Despite approval and rollout of COVID-19 vaccines, experts agree that even as the pandemic dies down in the coming months, SARS-CoV-2, the virus that causes the infectious disease, is likely here for the long haul (https://ibn.fm/1idh8). United Medical Equipment Business Solutions Network (“UME”) is here for the long haul too, commited to offering high-quality COVID-19 services, solutions and supplies. Among the supplies UME currently provides is the CareStart(TM) COVID-19 Antigen Rapid POC test.
Before COVID-19 was even declared a pandemic, the CareStart COVID-19 Antigen test had been authorized for use by the Federal Drug Administration (“FDA”) under an Emergency Use Authorization (“EUA”). “Due to the highly contagious nature and global spread, SARS-CoV-2 . . . continues to have devastating impacts on healthcare systems and the world economy, including the U.S.,” states CareStart COVID-19 Antigen packaging material approved by the FDA (https://ibn.fm/BIVxs).
“To effectively end the SARS-CoV02 pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical,” the information continues. “Particularly, the identification of subclinical or asymptomatic cases is important to reduce or stop the infection because these individuals may transmit the virus. As a point-of-care test with a 10 min testing time, CareStartCOVID-19 Antigen test allows effective screening of COVID-19 infection on a large scale.”
The CareStart antigen test can be administered by authorized laboratories and at the point of care by medical professionals to detect the presence of the SARS-CoV-2 nucleocapsid protein antigen (https://ibn.fm/qCkqU). The innovative test features a 10-minute processing time, identifies acute infection with 88.4% sensitivity and 100% specificity, and helps provide critical answers about active infections to patients and healthcare workers alike.
The CareStart product is part of a UME’s comprehensive COVID-19 monitoring strategy, which was carefully designed with the assistance of medical experts and includes ongoing, data-driven COVID-19 testing. United Medical Equipment Business Solutions is committed to being the leading provider of high-quality, reliable and transparent information and resources for all, particularly veterans and seniors. The company provides essential information and products that helps the community achieve optimal health and improve their quality of life.
In addition to the CareStart COVID-19 Antigen tests, UME provides a wide array of other COVID-19 supplies and products, including sanitizers, gloves and face shields, thermometers, hoods and masks.
UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and the medical community through its robust medication management and telehealth applications. In addition, the company recognizes the importance of being socially responsible as a corporation by giving back to the world through emergency assistance grants awarded to seniors, with an emphasis on veterans, by supporting nonprofits in their missions, and by supporting the American economy by providing work-at-home opportunities.
To learn more about this company, visit www.UnitedMedSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.